OKYO Pharma Limited
OKYOHealthcare|Biotechnology|GB
$1.43
+0.03 (+2.14%)
DCF Value
$0.21
Tangible Book / Share
$0.33
Cash / Share
$0.55
Financials
Financial Snapshot
Market Cap
$75.0M
Enterprise Value
$60.5M
Revenue (TTM)
$0.00
Net Income (TTM)
-$13.7M
Cash & Investments
$20.6M
Net Cash
$20.6M
Free Cash Flow (TTM)
-$7.8M
Operating CF (TTM)
-$7.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$20.6M
Quarterly Burn
$1.9M
Monthly Burn
$645.6K
Est. Runway
~10.6 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $16.9M | $0.00 | $627.6K | $235.0K | $6.9M | $2.7M | $4.0M | $826.8K | $1.6M | $20.6M | $20.6M | |
| Operating Cash Flow | -$651.3K | -$1.6M | -$2.0M | -$1.2M | -$1.6M | -$5.5M | -$7.7M | -$9.5M | -$1.8M | -$5.9M | -$7.7M | |
| Free Cash Flow | -$1.0M | -$1.6M | -$2.0M | -$1.2M | -$1.6M | -$5.5M | -$7.7M | -$9.5M | -$1.8M | -$5.9M | -$7.8M | |
| Capital Expenditure | -$375.4K | $0.00 | -$1.3K | $0.00 | -$6.9K | -$1.7K | -$5.9K | -$3.00 | -$1.2K | -$6.1K | -$7.3K | |
| Financing Cash Flow | $4.4K | $0.00 | $0.00 | $963.3K | $7.8M | $2.2M | $9.3M | $6.2M | $2.7M | $25.0M | $27.7M |
R&D Spending
R&D (TTM)
$4.1M
R&D Intensity
—
R&D Growth vs Prior
+124.6%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $3.0M | $517.5K | $348.3K | $1.6M | $6.3M | $8.2M | $2.3M | $1.8M | $4.1M | |
| SG&A | $363.2K | $573.4K | $1.9M | $995.4K | $3.0M | $4.9M | $6.7M | $0.00 | $4.9M | $0.00 | $12.3M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $219.17 | $6.0K | $811.5K | $13.0K | $6.7M | $7.5M | $2.6K | $6.7M | $3.1K | |
| Gross Profit | $0.00 | $0.00 | -$219.00 | -$6.0K | -$811.5K | -$13.0K | -$6.7M | -$7.5M | -$2.6K | -$6.7M | -$3.1K | |
| R&D | $0.00 | $0.00 | $3.0M | $517.5K | $348.3K | $1.6M | $6.3M | $8.2M | $2.3M | $1.8M | $4.1M | |
| SG&A | $363.2K | $573.4K | $1.9M | $995.4K | $3.0M | $4.9M | $6.7M | $0.00 | $4.9M | $0.00 | $12.3M | |
| Operating Income | -$363.0K | -$28.3M | -$4.5M | -$1.5M | -$4.1M | -$6.2M | -$13.1M | -$15.7M | -$7.2M | -$8.5M | -$16.4M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $1.2K | $1.1K | $0.00 | $96.7K | $1.1M | $883.6K | $473.9K | $1.3M | |
| Pretax Income | -$242.0K | -$28.3M | -$4.9M | -$1.6M | -$3.4M | -$6.2M | -$13.3M | -$16.8M | -$8.0M | -$8.9M | -$16.9M | |
| Net Income | -$243.0K | -$28.3M | -$4.9M | -$1.5M | -$3.4M | -$5.4M | -$13.3M | -$16.8M | -$4.7M | -$8.9M | -$13.7M | |
| EPS (Diluted) | -0.04 | -4.80 | -0.62 | -0.17 | -0.32 | -0.36 | -0.60 | -0.00 | -0.12 | -0.24 | -0.36 | |
| EBITDA | -$193.00 | $1.0M | -$4.5M | -$1.5M | -$4.1M | -$6.2M | -$13.1M | -$15.7M | -$7.1M | -$8.5M | -$15.6M | |
| Shares Out. (M) | 5.86 | 5.89 | 7.91 | 9.16 | 10.35 | 15.06 | 22.26 | 29.34 | 39.49 | 37.36 | 37.39 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $0.00 | $627.6K | $235.0K | $6.9M | $2.7M | $4.0M | $826.8K | $1.6M | $14.6M | $14.6M | |
| Short-Term Investments | $16.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.0M | $6.0M | |
| Total Current Assets | $16.9M | $47.65 | $758.8K | $566.7K | $7.0M | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M | $21.0M | |
| Total Assets | $0.00 | $0.00 | $759.9K | $597.4K | $7.1M | $4.3M | $5.2M | $1.5M | $3.7M | $21.0M | $21.0M | |
| Total Current Liabilities | $0.00 | $0.00 | $426.7K | $710.7K | $1.7M | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M | $8.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $0.00 | $0.00 | $426.7K | $737.2K | $1.8M | $1.4M | $7.3M | $7.4M | $9.2M | $8.6M | $8.6M | |
| Stockholders' Equity | $0.00 | $0.00 | $333.1K | -$139.8K | $5.3M | $2.9M | -$2.1M | -$5.9M | -$5.5M | $12.3M | $12.3M | |
| Retained Earnings | $0.00 | $0.00 | -$89.0M | -$85.9M | -$99.4M | -$112.4M | -$125.7M | -$142.5M | -$143.0M | -$152.0M | -$152.0M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$651.3K | -$1.6M | -$2.0M | -$1.2M | -$1.6M | -$5.5M | -$7.7M | -$9.5M | -$1.8M | -$5.9M | -$7.7M | |
| Capital Expenditure | -$375.4K | $0.00 | -$1.3K | $0.00 | -$6.9K | -$1.7K | -$5.9K | -$3.00 | -$1.2K | -$6.1K | -$7.3K | |
| Free Cash Flow | -$1.0M | -$1.6M | -$2.0M | -$1.2M | -$1.6M | -$5.5M | -$7.7M | -$9.5M | -$1.8M | -$5.9M | -$7.8M | |
| Investing Cash Flow | -$375.4K | $0.00 | -$1.3K | -$132.7K | -$18.1K | -$1.7K | -$5.9K | $0.00 | -$1.2K | -$6.0M | -$6.0M | |
| Financing Cash Flow | $4.4K | $0.00 | $0.00 | $963.3K | $7.8M | $2.2M | $9.3M | $6.2M | $2.7M | $25.0M | $27.7M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $990.6K | $230.0K | $1.4M | $7.3M | $6.2M | $1.7M | $25.0M | $26.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $4.4K | $0.00 | $0.00 | $0.00 | $7.6M | $0.00 | $2.0M | $0.00 | $950.0K | $0.00 | $950.0K | |
| Stock Based Comp. | $18.4K | $4.2K | $50.5K | $36.3K | $544.4K | $1.7M | $1.3M | $1.1M | $735.0K | $1.6M | $1.2K | |
| Net Change in Cash | -$651.3K | -$1.6M | -$2.0M | -$392.1K | $6.7M | -$4.2M | $1.3M | -$3.2M | $734.1K | $13.0M | $13.9M |
Dilution Tracker
Shares outstanding grew 260.9% over 5 years — significant dilution
Shares Outstanding
52M
5-Year Share Growth
+260.9%
Stock Issuance (TTM)
$26.7M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 5.86 | 5.89 | 7.91 | 9.16 | 10.35 | 15.06 | 22.26 | 29.34 | 39.49 | 37.36 | 37.39 | |
| Change vs Prior % | — | 0.5% | 34.2% | 15.9% | 13.0% | 45.5% | 47.7% | 31.8% | 34.6% | -5.4% | 0.1% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $990.6K | $230.0K | $1.4M | $7.3M | $6.2M | $1.7M | $25.0M | $26.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $18.4K | $4.2K | $50.5K | $36.3K | $544.4K | $1.7M | $1.3M | $1.1M | $735.0K | $1.6M | $1.2K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 0.0% | 0.0% | -1469.4% | 1103.1% | -63.1% | -184.3% | 646.4% | 286.2% | 84.8% | -72.6% | -200.7% | |
| ROA % | 0.0% | 0.0% | -644.2% | -258.1% | -47.3% | -126.3% | -255.0% | -1091.7% | -128.0% | -42.7% | -42.7% | |
| ROIC % | -2.2% | -59360666.8% | -1362.5% | 1325.9% | -75.7% | -184.6% | -8077.7% | 267.9% | 76.5% | -68.9% | -74.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | -2626.5% | -13490.6% | 98.4% | -51822.2% | -11.2% | 100.0% | -260942.1% | |
| Operating Income | 67.0% | -7692.3% | 84.0% | 66.5% | -172.2% | -50.7% | -110.0% | -20.3% | 54.4% | -18.2% | |
| Net Income | 70.4% | -11545.7% | 82.7% | 68.5% | -117.5% | -61.9% | -144.4% | -26.8% | 72.0% | -90.2% | |
| EPS (Diluted) | 70.5% | -11522.3% | 87.1% | 72.6% | -88.2% | -12.5% | -66.7% | 99.9% | -19900.0% | -100.0% | |
| Operating Cash Flow | -0.1% | -144.9% | -24.8% | 39.6% | -33.1% | -241.7% | -40.7% | -23.3% | 80.9% | -227.8% | |
| Free Cash Flow | 2.9% | -55.3% | -24.9% | 39.6% | -33.7% | -240.3% | -40.8% | -23.2% | 80.9% | -227.9% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | -83.0% | -32.7% | 362.2% | 293.7% | 30.1% | -72.7% | -19.7% | |
| SG&A Expense | -65.4% | 57.9% | 223.3% | -46.3% | 198.8% | 65.7% | 36.9% | -100.0% | 0.0% | -100.0% | |
| Total Assets | -100.0% | 0.0% | 0.0% | -21.4% | 1087.0% | -39.4% | 21.0% | -70.4% | 138.6% | 470.4% | |
| Book Value / Share | -100.0% | 0.0% | 0.0% | -136.2% | 3467.9% | -61.9% | -147.1% | -117.2% | 29.9% | 335.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 286.4% | -100.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.5% | 34.2% | 15.9% | 13.0% | 45.5% | 47.7% | 31.8% | 34.6% | -5.4% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B4.33
10Y Low / Med / High4.88 / 18.50 / 85.91
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.21
Tangible Book / Share
$0.33
Net Current Assets / Share
$0.23
Graham Net-Net
$0.32
Cash / Share
$0.55
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -87.65 | -0.75 | -5.84 | -21.29 | -11.31 | -10.06 | -2.80 | -2450.00 | -10.58 | -6.71 | -5.98 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | 0.00 | 85.91 | -237.22 | 7.04 | 18.50 | -18.21 | -7.34 | -9.04 | 4.88 | 4.33 | |
| EV/EBITDA | -109987.98 | 20.43 | -6.17 | -22.05 | -7.44 | -8.34 | -2.72 | -2.69 | -6.86 | -5.38 | -6.57 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-5.69
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $0.00 | $11.0M | $32.2M |
| Net Income | -$5.0M | -$15.1M | -$22.0M |
| EPS | $-0.14 | $-0.41 | $-0.59 |
| # Analysts (EPS) | 1 | 1 | 1 |